{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:08:52Z","timestamp":1789711732844,"version":"4.0.1"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Rheumatoid factor (RF), an autoantibody targeting IgG, is a key diagnostic marker of autoimmune diseases, especially rheumatoid arthritis (RA). In patients with RA, high RF titers have been reported to be associated with disease severity and may influence the pharmacological behavior and clinical response of certain biologic agents, including tumor necrosis factor (TNF) inhibitors. TNF inhibitors are widely used biologic agents in RA treatment and include two structure types: the fragment crystallizable (Fc)-containing protein (e.g. IgG) and the Fc-free protein. Clinical studies have suggested that in RA patients with high RF titers, sufficient circulating drug concentrations are more likely to be maintained with Fc-free TNF inhibitors than with Fc-containing TNF inhibitors. To clarify the mechanisms underlying this clinical observation, we investigated whether RF differentially alters FcRn-dependent recycling and macrophage uptake of the Fc-containing antibody adalimumab and the Fc-free, human serum albumin (HSA)-binding NANOBODY\n                    <jats:sup>\u00ae<\/jats:sup>\n                    compound ozoralizumab (OZR) using an ELISA-based RF-binding assay, an FcRn-mediated recycling assay in FcRn-expressing cells, and a mouse macrophage phagocytosis assay. In a RF binding assay, OZR showed minimal binding to RF. In the FcRn-mediated recycling assay, the recycling efficiency of OZR was not affected by high RF titers. In contrast, adalimumab, an IgG type of TNF inhibitor, exhibited clear interaction with RF and its recycling efficiency decreased in the presence of high RF titers. Furthermore, in a mouse macrophage phagocytosis assay, immune complexes containing the Fc-containing adalimumab, but not the Fc-free OZR, showed increased macrophage uptake in the presence of RF. In summary, our findings demonstrate that the HSA-binding property of OZR enables preservation of HSA-mediated FcRn recycling and avoids RF-enhanced immune-complex phagocytosis under high-RF conditions. These mechanisms may contribute to the maintenance of stable circulating concentrations and therapeutic efficacy of OZR in RA patients with high RF titers.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1927219","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:38:23Z","timestamp":1789709903000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Ozoralizumab, a trivalent anti-TNF\u03b1 NANOBODY\u00ae compound, is resistant to rheumatoid factor-mediated modulation of FcRn-dependent recycling and immune complex uptake"],"prefix":"10.3389","volume":"17","author":[{"given":"Mai","family":"Morimoto","sequence":"first","affiliation":[{"name":"Research Headquarters, Taisho Pharmaceutical Co., Ltd.","place":["Saitama, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihisa","family":"Sawa","sequence":"additional","affiliation":[{"name":"Research Headquarters, Taisho Pharmaceutical Co., Ltd.","place":["Saitama, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Ishiwatari-Ogata","sequence":"additional","affiliation":[{"name":"Research Headquarters, Taisho Pharmaceutical Co., Ltd.","place":["Saitama, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kojima","sequence":"additional","affiliation":[{"name":"Research Headquarters, Taisho Pharmaceutical Co., Ltd.","place":["Saitama, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Fujii","sequence":"additional","affiliation":[{"name":"Research Headquarters, Taisho Pharmaceutical Co., Ltd.","place":["Saitama, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2012.153","article-title":"Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment","volume":"8","author":"Schett","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00793-5","article-title":"Mechanisms of joint destruction in rheumatoid arthritis \u2014 immune cell\u2013fibroblast\u2013bone interactions","volume":"18","author":"Komatsu","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf003","article-title":"What is rheumatoid factor? From screening to personalized management","volume":"64","author":"Tanaka","year":"2025","journal-title":"Rheumatology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14051529","article-title":"Rheumatoid factor: Diagnostic and prognostic performance and therapeutic implications in rheumatoid arthritis","volume":"14","author":"Togashi","year":"2025","journal-title":"J Clin Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/6363086","article-title":"Autoantibodies as diagnostic markers and mediator of joint inflammation in arthritis","volume":"2019","author":"Fang","year":"2019","journal-title":"Mediators Inflammation"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1016263","article-title":"Rheumatoid factor IgM autoantibodies control IgG homeostasis","volume":"13","author":"Nicol\u00f2","year":"2022","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1136\/ard.2004.023523","article-title":"Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis","volume":"64","author":"De Rycke","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.060608","article-title":"High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor \u03b1 inhibitors in rheumatoid arthritis","volume":"66","author":"Bobbio-Pallavicini","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/ard.2007.084715","article-title":"Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis","volume":"68","author":"Potter","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13075-018-1544-9","article-title":"Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study","volume":"20","author":"Bluett","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-025-00769-3","article-title":"Influence of rheumatoid factors on the efficacy of TNF inhibitor therapy in patients with rheumatoid arthritis","volume":"12","author":"Nagayasu","year":"2025","journal-title":"Rheumatol Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae435","article-title":"Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis","volume":"63","author":"Smolen","year":"2024","journal-title":"Rheumatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"999\u20131005","DOI":"10.55563\/clinexprheumatol\/ig40gm","article-title":"Influence of rheumatoid factor on serum drug levels of TNF inhibitors with different structures in rheumatoid arthritis","volume":"49","author":"Mart\u00ednez-Feito","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1149874","article-title":"Unique structure of ozoralizumab, a trivalent anti-TNF\u03b1 NANOBODY\u00ae compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation","volume":"14","author":"Kyuuma","year":"2023","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.853008","article-title":"Ozoralizumab, a humanized anti-TNF\u03b1 NANOBODY\u00ae compound, exhibits efficacy not only at the onset of arthritis in a human TNF transgenic mouse but also during secondary failure of administration of an anti-TNF\u03b1 IgG","volume":"13","author":"Ishiwatari-Ogata","year":"2022","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.150454","article-title":"Structural design of the anti-TNF\u03b1 therapeutic NANOBODY\u00ae compound, ozoralizumab, to support its potent and sustained clinical efficacy","volume":"734","author":"Mima","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf171","article-title":"Ozoralizumab shows effectiveness regardless of baseline RF and ACPA titres in patients with RA: a post hoc analysis of the OHZORA trial","volume":"64","author":"Watanabe","year":"2025","journal-title":"Rheumatology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-05086-w","article-title":"Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study","volume":"42","author":"Nakayama","year":"2022","journal-title":"Rheumatol Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1461396","article-title":"Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients","volume":"11","author":"Plasencia-Rodr\u00edguez","year":"2024","journal-title":"Front Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf035","article-title":"Rheumatoid factors revisited in the age of biologic therapy","volume":"64","author":"Avci","year":"2025","journal-title":"Rheumatology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200809122","article-title":"The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity","volume":"185","author":"Tzaban","year":"2009","journal-title":"J Cell Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01540","article-title":"The neonatal Fc receptor (FcRn): A misnomer","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nri856","article-title":"Roles of Fc receptors in autoimmunity","volume":"2","author":"Takai","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00021","article-title":"Immunogenicity to biotherapeutics \u2013 the role of anti-drug immune complexes","volume":"7","author":"Krishna","year":"2016","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.057406","article-title":"Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis","volume":"66","author":"van der Laken","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1208\/s12248-026-01218-x","article-title":"In vivo clearance of immune complexes: Insights into human drug\/anti-drug antibody complex clearance dynamics","volume":"28","author":"Opolka-Hoffmann","year":"2026","journal-title":"AAPS J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-012-8318-y","article-title":"To B or not to B the conductor of rheumatoid arthritis orchestra","volume":"43","author":"Moura","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00682","article-title":"Unraveling the interaction between FcRn and albumin: Opportunities for design of albumin-based therapeutics","volume":"5","author":"Sand","year":"2015","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat Biotechnol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41467-018-03061-x","article-title":"A human endothelial cell-based recycling assay for screening of FcRn targeted molecules","volume":"9","author":"Grevys","year":"2018","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","first-page":"6073","DOI":"10.1038\/s41467-022-33764-1","article-title":"The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement","volume":"13","author":"Brinkhaus","year":"2022","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s42003-022-03787-x","article-title":"Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life","volume":"5","author":"Gj\u00f8lberg","year":"2022","journal-title":"Commun Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2024.06.013","article-title":"Cellular neonatal Fc receptor recycling efficiencies can differentiate target-independent clearance mechanisms of monoclonal antibodies","volume":"113","author":"Bryniarski","year":"2024","journal-title":"J Pharm Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M117.794248","article-title":"Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin","volume":"292","author":"Schmidt","year":"2017","journal-title":"J Biol Chem"},{"key":"B37","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s42003-025-08249-8","article-title":"Enhanced plasma half-life and efficacy of engineered human albumin-fused GLP-1 despite enzymatic cleavage of its C-terminal end","volume":"8","author":"Nilsen","year":"2025","journal-title":"Commun Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14699","article-title":"Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials","volume":"26","author":"Tanaka","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903296","article-title":"Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: A comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR","volume":"184","author":"Suzuki","year":"2010","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217624","article-title":"Immunoglobulin G structure and rheumatoid factor epitopes","volume":"14","author":"Maibom-Thomsen","year":"2019","journal-title":"PloS One"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M117.817064","article-title":"Half-life\u2013extended recombinant coagulation factor IX\u2013albumin fusion protein is recycled via the FcRn-mediated pathway","volume":"293","author":"Chia","year":"2018","journal-title":"J Biol Chem"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.549832","article-title":"Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding","volume":"289","author":"Andersen","year":"2014","journal-title":"J Biol Chem"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40591-016-0048-8","article-title":"Albumin-based drug delivery: Harnessing nature to cure disease","volume":"4","author":"Larsen","year":"2016","journal-title":"Mol Cell Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.164848","article-title":"Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain","volume":"286","author":"Andersen","year":"2010","journal-title":"J Biol Chem"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-006094","article-title":"Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trial","author":"Smolen","year":"","journal-title":"RMD Open"},{"key":"B46","first-page":"54","article-title":"IgG rheumatoid factor, complement and immune complexes in rheumatoid synovitis and vasculitis: Comparative and serial studies during cytotoxic therapy","volume":"43","author":"Scott","year":"1981","journal-title":"Clin Exp Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200501","article-title":"Impact of immune complex size and glycosylation on IgG binding to human Fc\u03b3Rs","volume":"190","author":"Lux","year":"2013","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-012-1100-8","article-title":"Cross-presentation of IgG-containing immune complexes","volume":"70","author":"Baker","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.079277","article-title":"Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys","volume":"313","author":"Rojas","year":"2005","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1927219\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:38:25Z","timestamp":1789709905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1927219\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2026.1927219"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1927219","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1927219"}}